RET and medullary thyroid gland carcinoma: RET alteration fosters unregulated activation of RET signalling, driving oncogenesis in MTC, and thus treatment depends on the use of multi-kinase inhibitors (exhibiting non-selective RET blockade) or selective RET TKIs such as selpercatinib.